Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Slugger who wrote (9562)	4/9/1999 1:25:00 PM
From: aknahow	Respond to of 17367

Sorry, forgot this years is the Second annual conference.

To: Slugger who wrote (9562)	4/9/1999 10:12:00 PM
From: aknahow	Respond to of 17367

XOMA is a client. home.att.net KMG partners Japanese and international biomedical companies through well-defined steps that ensure expedient market entry: Work with client company to determine the strategic traits sought in the partner company. Screen and evaluate potential partners and help management establish the critical internal support requirements. Maintain constant contact with and support the designated "alliance champion" within the partner candidate company to ensure the project keeps moving. Provide "insider" knowledge on market conditions, industry analysis and partner research through continuous briefings. Develop and implement an operating plan with managers from both sides of the alliance. Evaluate financing options and develop a range of strateties to ensure funding. Conduct the critical and frequent face-to-face meetings required on site in Japan, providing full representation on all issues of the client company. Negotiate on behalf of clients, utilizing bilingual capability and cross-cultural business expertise to structure the alliance agreement, determining a long-term perspective that also provides for an exit strategy. Provide for continuous representation after the alliance is structured to monitor operations and ensure smooth communications between the alliance parties. KMG Japan has established a solid record bringing to the clients successful strategic alliances, distribution agreements, and technology transfers, as well as market intelligence and regulatory victories. Alliances \| Industry Trends \| Articles \| Japanese Homepage

To: Slugger who wrote (9562)	4/10/1999 8:21:00 PM
From: aknahow	Respond to of 17367

A recommendation from Sutro would not hurt the stock. Unfortunately presenting at their conference and being recommended are two different things. Volume did pick up significantly on Friday. While there are no broker/dealer recommendations there are many biotech letter buy recommendations, (which have not helped the stock). I feel however that the letter recommendations are more objective than those of the broker/dealers. XOMA should wake up and realize that shareholders have more of an interest in their presentations than an estimated 80% of those that attend them in person. All of the following events have gone down without one word to long suffering shareholders about what was presented. March '99 International Symposium on Intensive Care and Emergency Medicine 14-19, Brussels, Belgium Pat Scannon, MD, PhD, rBPI-21 Clinical Update Bio Partnering Asia 8-9, Tokyo, Japan Jack Castello, CEO, Partnering Presentation American Chemical Society 21-25, Anaheim, CA Marc Better, PhD, Session Chair: Recent Developments in Expression Systems Pat Gavit, XOMA Scientist, "Isolation of Anti-fungal Peptides from Escherichia coli after Simultaneous in situ Lysis and Peptide Cleavage" April '99 Sutro & Co. Second Annual Healthcare Conference 7-9, San Diego, California Jack Castello, CEO, Corporate Presentation Yes, I know XOMA has a great I.R. Dept. Yes, I know they provide much more information than any other biotech company does on the Internet. And yet, and yet........